SEC Form D filing

TenNor Therapeutics (Suzhou) Ltd, 2026-05-26

An SEC Form D private-offering notice from Suzhou, a $14,699,667 filer-stated offering target in Biotech. Filed 2026-05-26. The source filing is one click away. For companies that filed this week, open the live feed.

What this filing says

Suzhou, China based clinical stage biotech developing therapies for bacterial infection and metabolic disease, including its lead H. pylori drug candidate rifasutenizol.

Filed 2026-05-26Filed to raise $14,699,667First money in 2026-05-12Raised so far $14,699,667HQ (as filed) SuzhouSector Biotech web-verified against the company’s own siteStage (inferred) EarlyCall status Non-US principal office
Source linked the Form D on EDGAR↗Website verified tennortherapeutics.com↗Named in the filing 11 executives & directors

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source